Glutathione
An antioxidant tripeptide discussed across immune, energy and longevity communities.
The short version
- Why people discuss it
- AxonRep’s community research identifies interest in glutathione for antioxidant support, immune health, energy, skin appearance and longevity. These themes span oral, topical and intravenous use, which cannot be combined into one efficacy claim.
- What it is
- A naturally occurring tripeptide and cellular antioxidant. Glutathione, its precursor NAC, oral supplements, topical preparations and sterile injections are different interventions.
- Biggest caution
- In August 2026, FDA reported at least 30 adverse events tied to injectable products compounded from dietary-supplement-grade glutathione, including sepsis-like symptoms and hospitalizations. Ingredient grade and sterile-product quality matter.
- Stack context
- NAC is often discussed as a way to influence glutathione status. NAC evidence and dosing do not establish a glutathione protocol, and neither validates multi-ingredient IV blends.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Source agreement describes reported practice, not clinical validation.
Oral
Community reference · Not clinical guidance- Amount
- 500–1,000 mg
- Frequency
- Once daily
- Duration / phase
- Ongoing in community use
Common oral pattern; injectable products have separate quality risks Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
100–200 mg SC daily or every other day for 4–8 weeks; maintenance 200 mg 1–2/week.
Evidence & sources · Route-specific evidence
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- FDA: August 2026 warning on dietary-grade glutathione injectablesRegulatory source · Checked 2026-09-12
- PubMed: randomized oral glutathione biomarker trialExisting research · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27